BCKDHB Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from human A-549 lung adenocarcinoma cells, with disruption of the BCKDHB gene encoding the E1 beta subunit of the branched-chain alpha-keto acid dehydrogenase (BCKDH) complex. This knockout eliminates BCKDH enzymatic activity, blocking decarboxylation of branched-chain alpha-keto acids from leucine, isoleucine, and valine. The polyclonal format offers a heterogeneous knockout model, avoiding clonal bottlenecks and enabling robust loss-of-function studies.
The host A-549 cell line is a well-characterized human lung carcinoma with epithelial morphology, derived from a 58-year-old Caucasian male. It is a model for non-small cell lung cancer (NSCLC) adenocarcinoma, widely used in cancer biology and metabolic research. Its genetic background, including KRAS and STK11 mutations, makes it relevant for studying metabolic rewiring and genotype-specific vulnerabilities.
BCKDHB is the E1 beta subunit of the BCKDH complex, which decarboxylates BCKAs to produce isovaleryl-CoA, isobutyryl-CoA, and alpha-methylbutyryl-CoA, feeding into acetyl-CoA and succinyl-CoA. It interacts with BCKDHA, DBT, DLD, and lipoic acid cofactor. BCKDH activity is regulated by BCKDK-mediated inactivation and PPM1K-mediated reactivation in response to BCAA levels and mitochondrial signals. Upstream, BCAT2 generates the initial keto acids, linking BCAA availability to complex function.
In A-549 lung adenocarcinoma, BCKDHB knockout disrupts BCAA catabolism, likely causing accumulation of leucine, isoleucine, valine, and their keto acids, which may alter metabolic signaling and exert toxic effects. Lung cancers often reprogram BCAA metabolism for biosynthesis and energy, and loss of BCKDH activity may shift metabolism toward glycolysis or glutaminolysis. This model enables study of BCAA oxidation in tumor proliferation, mitochondrial function, and redox homeostasis, especially in the context of KRAS and STK11 mutations.
Applications include metabolic reprogramming research in lung cancer, maple syrup urine disease modeling, mitochondrial metabolism studies, and drug screening for metabolic disorders. Typical assays encompass western blotting, BCKDH enzyme activity, LC-MS metabolomics, Seahorse metabolic flux analysis, proliferation assays, RT-qPCR, and RNA-seq. The cells are also suitable for co-culture and xenograft studies exploring BCAA metabolism in the tumor microenvironment. For further details, please contact Ascent Research.
